Reference : Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Physical, chemical, mathematical & earth Sciences : Chemistry
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/83685
Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate
English
Manette, Christine [Centre Hospitalier Universitaire de Liège - CHU > > Gynécologie-Obstétrique >]
Collette, Julien mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Sarlet, Nathalie [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Tancredi, Annalisa [Université de Liège - ULg > Département des sciences de la santé publique > Ecole de santé publique >]
Zegels, Brigitte [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
2006
Current Medicinal Chemistry
Bentham Science Publ Ltd
13
13
1585-1590
Yes (verified by ORBi)
International
0929-8673
Sharjah
[en] osteoporosis ; treatment ; fractures ; strontium ranelate
[en] In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated rat osteoclast, a preincubation of bone slices with strontium ranclate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. In a phase 11 dose ranging trial Strontium ranclate (500 mg. 1000 mg, 2000 mg/day) or placebo were given to 353 postmenopausal women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study. the annual increase in lumbar BMD of the group receiving 2000 mg of strontium ranclate was + 7.3%. a significant increase in bone alkaline phosphatase, over a 6-month period and a significant decrease in N-telopeptide crosslinks throughout the 2-year period were seen. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. The primary analysis of the SOTI study, evaluatine the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patient experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture by 16% in the group treated with strontium ranclate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture by 36% was also demonstrated in the patients at high risk of hip fracture (age >= 74 years and Femoral Neck T score <=-2.4 according to NHANES normative value).
http://hdl.handle.net/2268/83685

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Comprehensive therapy in osteoporosis using a single drug.pdfPublisher postprint720.12 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.